Tollys and Gustave Roussy enter into new research agreement

Prof. Guido Kroemer’s team, from Gustave Roussy, will test Tollys’ specific TLR3 agonist, TL-532, to restore deficient chemotherapeutic responses in the context of FPR1 deficiency. FPR1 deficiency affects 30% of world population and is associated with precocious manifestation of breast, colorectal, esophageal, head and neck carcinomas.

Dr Nasser Azli joins Tollys Scientific Advisory Board

Nasser Azli is a medical oncologist with over 30 years of academic and pharmaceutical experience. As an expert in clinical oncology and drug development, Nasser Azli is a highly valuable addition to our Scientific Advisory Board, particularly in view of the upcoming first clinical trials of our drug candidate TL-532.